EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Analysis of Soluble Interleukin‐2 Receptor as a Prognostic Biomarker in NMOSD and MOGAD

Philipp Klyscz iD, Carolin Otto, Klemens Ruprecht iD, Susanna Asseyer iD, Hannes Ole Tiedt iD, Christian Meisel, Judith Bellmann-Strobl, Friedemann Paul iD, Patrick Schindler iD

Annals of Clinical and Translational Neurology · 2025

DOI: 10.1002/acn3.70186 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, 2025. Verfasst von Philipp Klyscz und 8 weiteren Autor:innen. Beteiligte Einrichtung: Experimental and Clinical Research Center, a Cooperation Between Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité-…. Hauptthemen laut MEDLINE: Neuromyelitis Optica, Receptors, Interleukin-2, Myelin-Oligodendrocyte Glycoprotein. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Soluble interleukin‐2 receptor (sIL‐2R) is a biomarker for T cell activity. T cells are involved in neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody‐associated disease (MOGAD) pathogenesis. However, sIL‐2R has so far not been evaluated in these conditions. Here, we compared sIL‐2R levels in serum and cerebrospinal fluid (CSF) of patients with aquaporin‐4‐IgG‐seropositive and seronegative (AQP4‐IgG+/−) NMOSD, MOGAD, and noninflammatory neurologic disorders (NINDs), and assessed the prognostic value of sIL‐2R for future attacks.

Methods

Retrospective analysis of real‐world data of patients treated at Charité—Universitätsmedizin Berlin was conducted (45 MOGAD, 14 AQP4‐IgG+NMOSD, 10 AQP4‐IgG−NMOSD, 69 NINDs) between 2010 and 2024. Mean (SD) follow‐up time was 40 (35) months. sIL‐2R differences were assessed by linear mixed models. Cox regression analysis was performed to investigate the predictive value for subsequent attacks.

Results

Serum sIL‐2R was higher in AQP4‐IgG+NMOSD (estimated marginal mean [EMM] 802 IU/mL) and MOGAD (569 IU/mL) compared to NINDs (404 IU/mL). In patients with a first manifestation of MOGAD, but not NMOSD, serum sIL‐2R (HR = 9.07 [95% CI 1.37–60.01]) and CSF sIL‐2R (HR = 3.27 [95% CI 0.61–17.45]) levels were predictive for subsequent attacks.

Interpretation

Serum sIL‐2R is elevated in AQP4‐IgG+NMOSD and MOGAD and may be a prognostic biomarker for a relapsing disease course in MOGAD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuromyelitis OpticaReceptors, Interleukin-2Myelin-Oligodendrocyte GlycoproteinHumansMaleFemaleBiomarkersPrognosisMiddle AgedRetrospective StudiesAdultAquaporin 4AutoantibodiesAgedMyelin Oligodendrocyte Glycoprotein Antibody-Associated Disease

Stichwörter der Autor:innen

MOGADNMOSDbiomarkersoluble interleukin‐2 receptor

Substanzen

BiomarkersReceptors, Interleukin-2Myelin-Oligodendrocyte GlycoproteinAquaporin 4Autoantibodies

Autor:innen und Institutionen

  • Experimental and Clinical Research Center, a Cooperation Between Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Department of Neurology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Neuroscience Clinical Research Center (NCRC), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Division of Neuroimmunology, Department of Neurology, University of Heidelberg, Heidelberg, Germany.
  • Labor Berlin Charité-Vivantes GmbH, Berlin, Germany.

ORCID-Profile: Philipp Klyscz, Klemens Ruprecht, Susanna Asseyer, Hannes Ole Tiedt, Friedemann Paul, Patrick Schindler

Zitieren

APA

Klyscz, P., Otto, C., Ruprecht, K., Asseyer, S., Tiedt, H. O., Meisel, C., Bellmann-Strobl, J., Paul, F., & Schindler, P. (2025). Analysis of Soluble Interleukin‐2 Receptor as a Prognostic Biomarker in NMOSD and MOGAD. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.70186

Vancouver

Klyscz P, Otto C, Ruprecht K, Asseyer S, Tiedt HO, Meisel C, et al. Analysis of Soluble Interleukin‐2 Receptor as a Prognostic Biomarker in NMOSD and MOGAD. Annals of Clinical and Translational Neurology. 2025. doi:10.1002/acn3.70186

BibTeX
@article{Klyscz2025,
  author = {Klyscz, Philipp and Otto, Carolin and Ruprecht, Klemens and Asseyer, Susanna and Tiedt, Hannes Ole and Meisel, Christian and Bellmann-Strobl, Judith and Paul, Friedemann and Schindler, Patrick},
  title = {Analysis of Soluble Interleukin‐2 Receptor as a Prognostic Biomarker in NMOSD and MOGAD},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2025},
  doi = {10.1002/acn3.70186}
}
Kostenlos starten →